Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paridiprubart - Edesa Biotech

Drug Profile

Paridiprubart - Edesa Biotech

Alternative Names: EB 05; EB-07; NI-0101

Latest Information Update: 31 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovImmune SA
  • Developer Edesa Biotech; Light Chain Bioscience
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III SARS-CoV-2 acute respiratory disease
  • Phase II Rheumatoid arthritis
  • Phase I Systemic scleroderma

Most Recent Events

  • 10 Jul 2023 Edesa Biotech and US FDA agrees on primary endpoint for phase III trial in Adult respiratory distress syndrome
  • 28 Jun 2023 Pharmacodynamics data from preclinical trial in SARS-COV-2 acute respiratory distress syndrome released by Edesa Biotech
  • 11 May 2023 Edesa Biotech intends to obtain marketing approval for paridiprubart for the treatment of acute respiratory distress syndrome (ARDS) and and other conditions that involve dysregulated innate immune responses like systemic sclerosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top